Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease

Postgraduate Medical Journal

Volumn 83, Issue 978, 2007, Pages 277-280

  Deepak, D ^a   Furlong, N J ^b   Wilding, J P H ^a   MacFarlane, I A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ST HELENS AND KNOWSLEY TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DESMOPRESSIN; GROWTH HORMONE; HYDROCORTISONE; SEX HORMONE; THYROXINE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL EXAMINATION; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; HYPOTHALAMIC PITUITARY DISORDER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE DISEASE; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ADULT; AGED; BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOTHALAMIC DISEASES; LIPIDS; MALE; MIDDLE AGED; OBESITY; PITUITARY DISEASES;

EID: 34247549151     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.052241     Document Type: Article

References (27)

1. Bates AS, Van't HW, Jones PJ, et al. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169-72.
2. Erfurth EM, Hagmar L. Cerebrovascular disease in patients with pituitary tumors. Trends Endocrinol Metab 2005;16:334-42.
3. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8.
4. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-31.
5. McCallum RW, Petrie JR, Dominiczak AF, et al. Growth hormone deficiency and vascular risk. Clin Endocrinol (Oxf) 2002;57:11-24.
6. Mancini T, Kola B, Mantero F, et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf), 2004;61:768-77.
7. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4.
8. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52.
9. Leong KS, Walker AB, Martin I, et al. An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clin Endocrinol (Oxf) 2001;54:463-8.
10. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83:379-81.
11. WHO. Obesity: preventing and managing the global epidemic, WHO Technical Report Series, No 894. Geneva: World Health Organization, 2000.
12. International Diabetes Foundation. The IDF worldwide definition of the metabolic syndrome. Available from http://www.idf.org/home/index.cfm?node= 1429 (accessed 10 January 2007).
13. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis or individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
15. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
17. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
18. Blumenthal JA, Sherwood A, Gullette ECD, et al. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000;160:1947-58.
19. Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006;82:280-4.
20. Department of Health. Health survey for England 2004. Updating trends tables to include 2004 data. Available from http://www.ic.nhs.uk/pubs/ hlthsvyeng2004.upd (accessed 10 January 2007).
21. Daousi C, Dunn AJ, Foy PM, et al. Endocrine and neuroanatomy features associated with weight gain and obesity in adult patients with hypothalamic damage. Am J Med 2005;118:45-50.
22. Malik IA, Foy P, Wallymahmed M, et al. Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. Clin Endocrinol (Oxf) 2003;59:75-81.
23. National Institute of Clinical Excellence. Full guideline: type 2 diabetes - management of blood glucose levels, 2002. Available from http://www.nice.org.uk/guidance/CGG (accessed 10 January 2007).
24. National Institute of Clinical Excellence. Full guideline: type 2 diabetes - blood pressure management, 2002. Available from nttp://www.nice.org. uk/guidance/CGH (accessed 10 January 2007).
25. National Institute of Clinical Excellence. Full guideline: type 2 diabetes - lipids management, 2002. Available from http://www.nice.org.uk/ guidance/CGH (accessed 10 January 2007).
26. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006;29(Suppl 1):S4-42.
27. Clayton RN, Wass JAH. Pituitary tumours: recommendations for service provision and guidelines for management of patients. Consensus statement of a working party. J R Coll Physicians Lond 1997;31:628-36.